Eli Lilly warns hospitals to submit claims data or lose 340B drug discounts

Eli Lilly issued a direct warning to hospitals participating in the federal 340B drug discount program: submit required claims data within the next five days or lose access to discounts on its products. This enforcement action stems from Lilly's policy, implemented earlier this year, requiring 340B entities to provide detailed data on how discounted drugs are dispensed. Hospitals that fail to comply by the deadline risk a significant increase in drug acquisition costs. This move intensifies the ongoing conflict between drug manufacturers and 340B providers over program transparency. Affected hospital pharmacies and affiliated clinics must confirm their data submission status immediately to avoid financial disruption.